Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

RECORDATI GROUP is the lead sponsor of 7 current clinical trials in our UK and USA registers. 4 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Carglumic Acid and Osilodrostat. The most-studied condition is Methylmalonic Acidemia.

ClinicalTrials.gov trials by status

Recruiting457%
Active, closed343%

Trials by phase

Observational571%
Phase 2229%

Clinical trials sponsored by RECORDATI GROUP

7 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome NCT03708900 · Cushing Syndrome Drug: Osilodrostat	Phase 2	Recruiting	2021-04	UK, USA
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta NCT04253015 · ClinicalTrials.gov ↗ · Neuroblastoma	Observational	Recruiting	2019-09	UK
Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach NCT04176523 · ClinicalTrials.gov ↗ · Methylmalonic Acidemia, Propionic Acidemia Drug: Carglumic Acid	Observational	Recruiting	2019-01	UK
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics NCT05040178 · ClinicalTrials.gov ↗ · Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia Drug: Carglumic Acid	Observational	Recruiting	2022-06	USA
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome NCT05382156 · Endogenous Cushing's Syndrome Drug: Osilodrostat	Observational	Active, closed	2022-06	USA
Cold Agglutinin Disease Real World Evidence Registry NCT05791708 · ClinicalTrials.gov ↗ · Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)	Observational	Active, closed	2019-12	UK, USA
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia NCT05928390 · ClinicalTrials.gov ↗ · Post-Bariatric Hypoglycemia	Phase 2	Active, closed	2024-01	UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in RECORDATI GROUP trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Carglumic Acid2 Osilodrostat2

Conditions in RECORDATI GROUP trials

9 conditions

Methylmalonic Acidemia2Propionic Acidemia2Cushing Syndrome1Neuroblastoma1Cold Agglutinin Disease (CAD)1Cold Agglutinin Syndrome (CAS)1Post-Bariatric Hypoglycemia1Endogenous Cushing's Syndrome1Hyperammonemia1

By trial register

Register	Trials	Recruiting
Clinical trials in UK	5	3
Clinical trials in USA	5	2

A trial with sites in more than one country appears in each of those registers.

Questions about RECORDATI GROUP trials

How many clinical trials does RECORDATI GROUP sponsor?

RECORDATI GROUP is the lead sponsor of 7 current trials on ClinicalTrials.gov in our UK and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are RECORDATI GROUP trials recruiting?

Yes. 4 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is RECORDATI GROUP testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Carglumic Acid (2) and Osilodrostat (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

RECORDATI GROUP clinical trials